Composition : Ribavirin USP 200 mg.
Indications : Ribavirin is used in
combination with Interferon /PegInterferon
and other oral anti-viral drugs
such as Sofosbuvir to treat patients with
Chronic Hepatitis C (CHC).
Dosage and Administration : Ribavirin
capsule is taken orally two times daily
with food at a consistent manner. These
indications are based on achieving
unnoticeable HCV-RNA after treatment
for 24 or 48 weeks and maintaining a
Sustained Virologic Response (SVR) 24
weeks after the last dose. The
Recommended dosage of Ribavirin in
the combination therapy is given below :
1) The daily dose of Ribavirin +
Interferon alpha-2a/Interferon alpha-2b
(3 MIU 3 times weekly
≤75 kg = (400+600) mg for 48
weeks (Genotype 1 & 4).
ii) >75 kg = (600+600) mg for 24
weeks (Genotype 2 & 3).
2) Ribavirin daily dose with PegInterferon
alpha -2b (180 µgm once weekly
i) <75 kg=
(600+600) mg for 48 weeks (Genotype
1 & 4). ii) (400+400) mg for 24 weeks
(Genotype 2 & 3). Or, as directed by the
Use in pregnancy and lactation : Ribavirin must not be used during pregnancy. It is not known whether this drug passes into breast milk. Caution should be advised highly for the administration of Ribavirin to nursing women to avoid any serious adverse reactions in infants.
Packing : Opegus : 3 x 7's capsules in blister pack.